LEO PHARMA LAUNCHES AD DAYS AROUND THE WORLD CAMPAIGN TO RAISE AWARENESS OF THE IMPACT OF ATOPIC DERMATITIS ACROSS CULTURES
BALLERUP, Denmark, 3 October 2022– LEO Pharma A/S, a global leader in medical dermatology, today launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD) – the most common form of eczema.1 In collaboration with patient advocacy organizations in France, Italy, Germany and Spain, the campaign shares real patient stories to educate and inform people living with AD that regardless of nationality or culture, there is hope to triumph over adversity, despite common everyday challenges.
The campaign features Global patient advocate Ashley Ann Lora, who travels from the United States to France, Italy, Germany and Spain to meet with and document the emotionally compelling stories of four women – Marjolaine, Laura, Julia and África – who are living with AD, each at a different stage in their life. Through in-depth interviews, the documentary-style videos show audiences what it is like to live with and navigate the challenges associated with AD, and showcase how each of these resilient women has found peace, joy and empowerment over time. Their shared experiences and advice are as inspirational as they are informative.
“People don’t see eczema as a big deal, but it can cause so much suffering,” explained Ashley Ann Lora. “My hope is that the experiences shared through these stories will help people living with AD feel seen, heard and connected to others around the world with this condition. I also hope these personal stories help others gain a better understanding of their own eczema and their relationship with this condition. People living with AD don’t have to suffer; there are resources to help manage the condition and ways to enjoy life alongside it.”
“Atopic dermatitis is about more than just skin, and you never know where you might find your healing. For me, discovering dance and movement therapy transformed the way I see my eczema and today is a very important part of how I manage my condition,” said Marjolaine, a patient advocate living in France. “It is not one size fits all and different things will work for different people. I hope that my story will help others battling with atopic dermatitis to find what works for them.”
The campaign offers access to these inspiring stories through www.ADDaysAroundTheWorld.com. Patients living with AD can watch the full video series featuring each patient advocate, learn more about AD, download a discussion guide to help facilitate better conversations with their healthcare professionals and access information about local patient advocacy organizations in each country.
“LEO Pharma is proud to have the opportunity to work with these inspiring patient advocates on AD Days Around the World. We know dermatology goes beyond the skin, and in our industry, we have the responsibility to see the whole patient when it comes to care,” said Christophe Bourdon Chief Executive Officer, LEO Pharma A/S.“Our hope is that through this campaign, and the inspiring stories of África, Laura, Julia and Marjolaine, other people living with AD realize there is life beyond an AD diagnosis and resources available to help them manage their skin condition.”
About atopic dermatitis
Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.2 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.3
About Ashley Ann Lora
Global patient advocate and campaign host Ashley Ann Lora has been living with AD for more than 25 years. As a passionate global advocate, she uses the power of vulnerability to speak up for patients and advises on the needs of the AD community. Through her social platform, she is able to connect with others to share her journey of living with AD and provide hope and optimism for others.
- - -
References
- National Eczema Association. What is atopic dermatitis? https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/
- Weidinger S, et al. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
- Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246.
Contacts
Contact:
David Patti
LEO Pharma, Global Product Communications
+1 973 796 7706
DAPAI@leo-pharma.com
Jes Broe Frederiksen
LEO Pharma, Global Product Communications
+45 53 60 59 48
JEBFE@leo-pharma.com
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,200 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference7.1.2026 13:00:00 CET | Pressemeddelelse
Ballerup, Denmark, January 7, 2026 – LEO Pharma, a global leader in medical dermatology, announced today that CEO Christophe Bourdon will deliver a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 9:00 AM PST. With over 60 years of specialist expertise in medical dermatology and more than 90 million patients served in 70+ markets, LEO Pharma is uniquely positioned in one of healthcare’s most attractive and underserved sectors. Backed by an unmatched portfolio combining category‑leading brands with first‑in‑class innovations, the company is redefining standards of care for patients with high unmet needs. Entering 2026, LEO Pharma builds on the strong momentum of recent years, marked by robust top-line growth, significant margin expansion, and a promising pipeline. Leveraging its unique global platform, the LEO Pharma is advancing innovation as the preferred partner in medical dermatology. The J.P. Morgan Healthcare Con
LEO Pharma appoints Marika Murto to lead Global Product Strategy16.12.2025 09:00:00 CET | Pressemeddelelse
Marika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma’s portfolio potential, driving patient impact and supporting sustainable growth
LEO Pharma submits adolescent label expansion application for Anzupgo® to EMA15.12.2025 09:00:00 CET | Pressemeddelelse
LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | Pressemeddelelse
The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
